The letter advises that the update to the special warnings and precautions section includes advice on:
- Weight gain - should be monitored and managed as clinically appropriate.
- Hyperglycaemia - hyperglycaemia and/or development or exacerbation of diabetes has been reported rarely but has been fatal in some cases. It is recommended that patients are monitored for observed for signs and symptoms of hyperglycaemia or worsening diabetes control and managed as appropriate.
- Metabolic Risk - it is suggested that the observed changes in weight, blood glucose and lipids may result in an increased metabolic risk. This should be managed as clinically appropriate.
Action: The metabolic risks posed by second generation (atypical) antipsychotics are well known. This update reminds clinicians of the need to monitor for these effects and intervene where appropriate.
|« Review of aliskiren announced||New aspirin meta-analysis »|